Rebekka Wehner

Dresden, SN 01307, Germany

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 61 publications

Patient-derived resources for decoding and targeting brain metastases ecosystems.

Patient-derived resources for decoding and targeting brain metastases ecosystems.

Journal: EMBO molecular medicine

Published: February 22, 2026

Tumor-infiltrating CD8+Ki-67+ and CD8+LAG-3+ T cells are associated with improved patient survival in retroperitoneal dedifferentiated liposarcomas and leiomyosarcomas.

Tumor-infiltrating CD8+Ki-67+ and CD8+LAG-3+ T cells are associated with improved patient survival in retroperitoneal dedifferentiated liposarcomas and leiomyosarcomas.

Journal: Experimental and molecular pathology

Published: February 10, 2026

Preclinical efficacy of tasquinimod in myelodysplastic neoplasms: Restoring erythropoiesis and mitigating bone loss.

Preclinical efficacy of tasquinimod in myelodysplastic neoplasms: Restoring erythropoiesis and mitigating bone loss.

Journal: HemaSphere

Published: September 01, 2025

Automated GMP-compatible production of universal CAR Tregs for organ-targeted tolerance induction.

Automated GMP-compatible production of universal CAR Tregs for organ-targeted tolerance induction.

Journal: Journal of translational medicine

Published: August 18, 2025

Azacitidine to treat measurable residual disease in patients with MDS/AML: final long-term results of the RELAZA2 trial.

Azacitidine to treat measurable residual disease in patients with MDS/AML: final long-term results of the RELAZA2 trial.

Journal: Blood

Published: July 21, 2025

Azacitidine to treat measurable residual disease in patients with MDS/AML: final long-term results of the RELAZA2 trial.

Azacitidine to treat measurable residual disease in patients with MDS/AML: final long-term results of the RELAZA2 trial.

Journal: Blood

Published: July 21, 2025

Profiling autoantibodies at baseline and during immune checkpoint inhibitor therapy of renal cell carcinoma patients-exploratory results from TITAN-RCC.

Profiling autoantibodies at baseline and during immune checkpoint inhibitor therapy of renal cell carcinoma patients-exploratory results from TITAN-RCC.

Journal: ESMO open

Published: May 12, 2025

Multi-compartment immune cell profiling highlights the prognostic relevance of CD127+ CD8+ T cells for patients with high-grade serous ovarian cancer.

Multi-compartment immune cell profiling highlights the prognostic relevance of CD127+ CD8+ T cells for patients with high-grade serous ovarian cancer.

Journal: Frontiers in immunology

Published: April 07, 2025

Tertiary Lymphoid Structures Are Associated with Progression-Free Survival of Peripheral Neuroblastic Tumor Patients.

Tertiary Lymphoid Structures Are Associated with Progression-Free Survival of Peripheral Neuroblastic Tumor Patients.

Journal: Cancers

Published: February 27, 2025

Combining T cell receptor sequencing and transcriptomics to characterize tissue-resident T cells from human gut biopsies.

Combining T cell receptor sequencing and transcriptomics to characterize tissue-resident T cells from human gut biopsies.

Journal: Biochemical and biophysical research communications

Published: January 15, 2025

Inflammatory stromal and T cells mediate human bone marrow niche remodeling in clonal hematopoiesis and myelodysplasia.

Inflammatory stromal and T cells mediate human bone marrow niche remodeling in clonal hematopoiesis and myelodysplasia.

Journal: Nature communications

Published: December 19, 2024

Inflammatory Mesenchymal Stromal Cells and IFN-responsive T cells are key mediators of human bone marrow niche remodeling in CHIP and MDS.

Inflammatory Mesenchymal Stromal Cells and IFN-responsive T cells are key mediators of human bone marrow niche remodeling in CHIP and MDS.

Journal: bioRxiv : the preprint server for biology

Published: December 09, 2024

Showing 1-12 of 61

Last Updated: 09/26/2026